In addition, our genetic mutation rates in EOPSP are based on pathogenic mutations that are directly genotyped on the Illumina NeuroChip, and targeted NPC1 and NPC2 sequencing was limited to cases that had biochemical evidence of Niemann‐Pick type C disease. This evidence concerns the gene NPC1 and Niemann-Pick disease type C.